Launched in September 2018 by the National Heart, Lung, and Blood Institute (NHLBI), the Cure Sickle Cell Initiative is a research effort dedicated towards accelerating promising genetic therapies to cure sickle cell disease. Actively engaging the sickle cell disease community and exploring the scientific questions needed to safely and effectively advance potential therapies, the Initiative's aim is to move the most promising genetic therapies safely into clinical trials within 5-10 years.
